On March 29, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of "The Top Line," Fierce Pharma staff writer Fraiser Kansteiner concludes our miniseries to explore what that means for the opioid epidemic. We'll also cover a possible over-the-counter birth control, a COVID test recall, plus this week's headlines.
To learn more about the topics in this episode:
- We want your stories: Biopharma's collective memory of COVID—in photographs
- Lilly's hotly anticipated Alzheimer's data set a new high score in slowing cognitive decline
- Baxter breaks off biopharma solutions segment in $4.25B private equity deal
- Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say
- Roche, SD Biosensor recall 500,000 at-home COVID tests due to bacteria risks
- Perrigo's OTC birth control pill aces FDA expert meeting
- Emergent makes history with first FDA nod for over-the-counter naloxone
- Ahead of next month's FDA decision, Emergent aces AdComm for over-the-counter Narcan nod
"The Top Line" is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.